NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division - Seite 3
Follow us on social media and stay up to date on all of our developments:
https://www.linkedin.com/company/64892686
https://twitter.com/novaccessglobal
ABOUT CKN VENTURES, LTD.
CKN Ventures is a group of technology companies based in Thailand with offices and facilities in Thailand and Singapore and serving both ASEAN and international regions. We focus on advanced diagnostics and technology-based precision medicine that enables physicians to deliver personalized care to patients with Cancer and other chronic or infectious diseases. Founded in 2019 we apply advanced technologies and artificial intelligence (AI) to process diverse peer reviewed data (genome, medical test results, medications, lifestyle etc.) on patients and utilize the latest medical research to generate personalized prescriptions/care plans. The personalized care plans go beyond the current standard-of-care and utilize targeted combinations of existing treatments to deliver better patient outcomes for target diseases as well as lowering healthcare costs. Physicians use our care plans as a guide to treat patients uniquely based on analysis including a battery of existing clinical tests, their genome, and their disease status, and do so in a fast and economical package.
Lesen Sie auch
Our initial products address the spectrum of cancers with a personalized combination therapy which deliver better patient outcomes than the standard-of-care. Physicians are provided with a detailed and comprehensive report which outlines individual genomic details and suggests the most appropriate therapies to administer based on individual genetic analysis. The AI based software which creates Physician Reports is regularly updated as new therapeutic techniques and drugs are constantly being developed, published, and approved.
CKN also owns and manages registered diagnostic labs outfitted with State-of-the-Art equipment and highly trained personnel. We have a catalogue of esoteric molecular and immunological diagnostic assays and also create and develop our own "LDT's" (Lab Developed Tests), including reagents, testing formats, and equipment/automation.
The Company is also developing a distribution network to sell the diagnostic kits and processes we acquire and develop to hospitals and clinical lab networks throughout ASEAN countries. We are creating a combination of in-house sales force and large regional corporate partnerships for distribution of registered kits and select genomic sequencing services for cancers. CKN also is highly experienced in Regulatory Approvals and running Clinical Trials.